ImmunoGen touts new drug-delivering antibodies

Tuesday, March 8, 2011 10:33 AM

After forming partnerships with several major pharmaceutical companies, Waltham, Mass.-based biotech ImmunoGen wants to boost its pipeline of antibody-drug conjugates.

ImmunoGen is known for providing the technology for Roche/Genentech's experimental T-DM1, enabling a cancer-killing toxin to be linked to the approved antibody drug Herceptin to treat certain patients with breast cancer. While that is the latest-stage candidate to use ImmunoGen's technology, the firm has its own compounds that could bolster its future prospects.

One of the compounds in an early-stage clinical trial, called IMGN529, is an antibody that targets non-Hodgkin's lymphomas and that includes a special toxin. The toxin is supposed to remain linked to the antibody in a patient's bloodstream, until the compound reaches the targeted cancer site. This approach targets specific tumors with the antibody while delivering a potent toxin against the cancer. ImmunoGen aims to file with the FDA by mid-2011 for approval to begin early human trials with the new compound.

Share:          
CWWeekly

March 23

Industry welcomes FDA draft guidance outlining the use of electronic Informed Consent for trials

Apple launches ResearchKit platform to tap millions of iPhone users to enroll in observational studies using apps

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs